Association of tumor necrosis factor-α gene promoter polymorphism at sites -308 and -238 with non-alcoholic fatty liver disease: A meta-analysis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 4, 2012, Pages 670-676

  Wang, Ji kai ^a   Feng, Zhe wei ^a   Li, Ying chun ^a   Li, Qing yan ^a   Tao, Xing yong ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Meta analysis; Non alcoholic fatty liver disease; Polymorphism; Tumor necrosis factor alpha

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENOTYPE; HUMAN; META ANALYSIS (TOPIC); NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROMOTER REGION; REVIEW;

EID: 84863377228     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06978.x     Document Type: Review

References (35)

1. Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 2010; 7: 195-203.
2. Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu. Rev. Pathol. 2010; 5: 145-71.
3. Gaemers IC, Groen AK. New insights in the pathogenesis of non-alcoholic fatty liver disease. Curr. Opin. Lipidol. 2006; 17: 268-73.
4. Kogiso T, Moriyoshi Y, Nagahara H. Clinical significance of fatty liver associated with metabolic syndrome. Hepatol. Res. 2007; 37: 711-21.
5. Streba LA, Carstea D, Mitrut P, Vere CC, Dragomir N, Streba CT. Nonalcoholic fatty liver disease and metabolic syndrome: a concise review. Rom. J. Morphol. Embryol. 2008; 49: 13-20.
6. Marchesini G, Brizi M, Morselli-Labate AM etal. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 1999; 107: 450-5.
7. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N. Engl. J. Med. 2000; 343: 1467-76.
8. Seki S, Kitada T, Sakaguchi H. Clinicopathological significance of oxidative cellular damage in non-alcoholic fatty liver diseases. Hepatol. Res. 2005; 33: 132-4.
9. Osterreicher CH, Brenner DA. The genetics of nonalcoholic fatty liver disease. Ann. Hepatol. 2007; 6: 83-8.
10. Hajeer AH, Hutchinson IV. Influence of TNFalpha gene polymorphisms on TNFalpha production and disease. Hum. Immunol. 2001; 62: 1191-9.
11. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994; 43: 1271-8.
12. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996; 271: 665-8.
13. Roden M, Price TB, Perseghin G etal. Mechanism of free fatty acid-induced insulin resistance in humans. J. Clin. Invest. 1996; 97: 2859-65.
14. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004; 40: 46-54.
15. Wong VW, Hui AY, Tsang SW etal. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2006; 4: 1154-61.
16. Bayley JP, de Rooij H, van den Elsen PJ, Huizinga TW, Verweij CL. Functional analysis of linker-scan mutants spanning the -376, -308, -244, and -238 polymorphic sites of the TNF-alpha promoter. Cytokine 2001; 14: 316-23.
17. Valenti L, Fracanzani AL, Dongiovanni P etal. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 274-80.
18. Huang J, Li YY, Zhou YJ. Association between tumor necrosis factor-alpha gene polymorphism and insulin resistance in nonalcoholic fatty liver disease. Zhonghua Gan Zang Bing Za Zhi 2006; 14: 613-15.
19. Tokushige K, Takakura M, Tsuchiya-Matsushita N, Taniai M, Hashimoto E, Shiratori K. Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. J. Hepatol. 2007; 46: 1104-10.
20. Wong VW, Wong GL, Tsang SW etal. Genetic polymorphisms of adiponectin and tumor necrosis factor-alpha and nonalcoholic fatty liver disease in Chinese people. J. Gastroenterol. Hepatol. 2008; 23: 914-21.
21. Hu ZW, Luo HB, Xu YM etal. Tumor necrosis factor-alpha gene promoter polymorphisms in Chinese patients with nonalcoholic fatty liver diseases. Acta Gastroenterol Belg. 2009; 72: 215-21.
22. Aller R, de Luis DA, Izaola O etal. G308A polymorphism of TNF-alpha gene is associated with insulin resistance and histological changes in non alcoholic fatty liver disease patients. Ann. Hepatol. 2010; 9: 439-44.
23. Zhou YJ, Li YY, Nie YQ etal. Influence of polygenetic polymorphisms on the susceptibility to non-alcoholic fatty liver disease of Chinese people. J. Gastroenterol. Hepatol. 2010; 25: 772-7.
24. Trujillo-Murillo K, Bosques-Padilla FJ, Calderón-Lozano I etal. Association of tumor necrosis factor α and manganese superoxide dismutase polymorphisms in patients with non-alcoholic steatohepatitis from northeast Mexico. Open Hepatol. J. 2011; 3: 1-6.
25. Alisi A, Nobili V. Molecular genetics of NASH: the role of polymorphisms. J. Hepatol. 2007; 47: 868-9. Author reply 870-861.
26. Wilfred de Alwis NM, Day CP. Genes and nonalcoholic fatty liver disease. Curr. Diab. Rep. 2008; 8: 156-63.
27. Tilg H, Moschen AR. Relevance of TNF-alpha gene polymorphisms in nonalcoholic fatty liver disease. Expert Rev. Gastroenterol. Hepatol. 2011; 5: 155-8.
28. Frigerio S, Ciusani E, Pozzi A, Silvani A, Salmaggi A, Boiardi A. Tumor necrosis factor microsatellite polymorphisms in Italian glioblastoma patients. Cancer Genet. Cytogenet. 1999; 109: 172-4.
29. Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LB, Duff GW. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J. Exp. Med. 1993; 177: 557-60.
30. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997; 389: 610-14.
31. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol. Metab. 2003; 14: 137-45.
32. Ji ZZ, Dai Z, Xu YC. A new tumor necrosis factor (TNF)-alpha regulator, lipopolysaccharides-induced TNF-alpha factor, is associated with obesity and insulin resistance. Chin. Med. J. 2011; 124: 177-82.
33. Endo M, Masaki T, Seike M, Yoshimatsu H. TNF-alpha induces hepatic steatosis in mice by enhancing gene expression of sterol regulatory element binding protein-1c (SREBP-1c). Exp. Biol. Med. (Maywood) 2007; 232: 614-21.
34. Iubitskaia NS, Antoniuk MV, Veremchuk LV, Khodosova KK. Role of tumor necrosis factor in the development of metabolic syndrome. Ter. Arkh. 2009; 81: 59-63.
35. Angelico F, Del Ben M, Conti R etal. Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases. J. Gastroenterol. Hepatol. 2003; 18: 588-94.